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Abstract
IL-21 is a key T-cell growth factor (TCGF) involved in innate and adaptive immune response.
It contributes to the proliferation of naive, but not memory T lymphocytes. However, the full spectrum
of IL-21 activity on T cells remains unclear. Here, we demonstrate that IL-21 primarily maintains the
expression of specific naive cell surface markers such as CD45RA, CD27, CD62L and CCR7 on human
CD41 T lymphocytes and that the expression of CCR7 induces cell migration by means of CCL21
chemoattraction. These effects contrast with those of IL-2 which induced the marked proliferation of
CD41 T lymphocytes, leading to an activated-memory phenotype. Nevertheless, IL-21 maintained cell
cycle activation and expression of proliferation markers, including proliferating cell nuclear antigen
and Ki-67, and triggered T-cell proliferation via TCR and co-stimulation pathways. Unlike IL-2, IL-21
decreased the expression of the anti-apoptotic Bcl-2 protein, which correlated with the absence of
activation of the phosphatidylinositol 3#-kinase/Akt signaling pathway. Thus, IL-21 is a TCGF whose
function is the preservation of a pool of CD41 T lymphocytes in a naive phenotype, with a low
proliferation rate but with the persistence of cell cycling proteins and cell surface expression of CCR7.
These findings strongly suggest that IL-21 plays a part in innate and adaptive immune response
owing to homeostasis of T cells and their homing to secondary lymphoid organs.
Introduction
IL-21 is a member of the T-cell growth factor (TCGF) family,
as are IL-2 and IL-15. TCGFs contribute to allograft rejection
and the development of autoimmune and chronic inflamma-
tory diseases by promoting activation, proliferation and infil-
tration of immune cells within the target organ (1–6). IL-21
may be involved in hematopoietic development and differen-
tiation of NK cells, as well as in the activation and prolifera-
tion of B cells and co-stimulation of naive, but not memory,
T cells (7–9). Unlike IL-2 and IL-15, IL-21 has no significant
effect on the proliferation of T cells in the absence of anti-
CD3 or other stimuli (7). Activated CD4+ T cells, Th2 cells for
some authors (10) or memory CD4+ T cells polarized toward
Th1 or Th17 by others (11), also produce IL-21, suggesting
that IL-21 may play an autocrine/paracrine role in the regula-
tion of the immune response. IL-21 signals through the com-
mon c chain as do IL-2 and IL-15, but it also binds with
high affinity to a single receptor chain, IL-21 (7, 12). Ligation
to their receptor subunits may contribute to the distinct
effects of IL-2, IL-15 and IL-21 as ligand binding is associ-
ated with different intracellular signals (13), including Janus
kinase (Jak) and signal transducers and activators of tran-
scription (STAT) pathways. The phosphatidylinositol 3#-kinase
(PI3K)/Akt pathway is also a common signaling component
of cytokine members of the IL-2 family, as it is mediated by
the S region of the intracellular tail of IL-2Rb (14). In turn,
the ability of IL-2 to activate Akt results in the inhibition of
apoptosis and stimulation of cell proliferation as Akt clearly
regulates the expression of Bcl-2 and c-myc (14). Akt activa-
tion may determine whether activated T cells undergo apo-
ptosis or persist as regulatory/memory cells after robust
immune activation, the key to peripheral T cell homeostasis.
IL-21 is also a cc-dependent cytokine, but its receptor does
not possess the IL-2Rb chain as do IL-2R or IL-15R. There-
fore, IL-21 may not induce proliferation of T cells via the
same intracellular signaling pathway.
IL-21 is produced by activated CD4+ T cells, but its func-
tional effects on human naive CD4+ T cells are poorly char-
acterized and they seem to be less marked than its effects
on CD8+ T cells. Moreover, according to an increasing number
of reports, the effects of IL-21 on human immune cells as
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compared with murine cells are conflicting (15–18). The pres-
ent study pinpoints a novel role for IL-21 on naive T lympho-
cytes. This TCGF is necessary to conserve the naive
phenotype of a pool of CD4+ T lymphocytes which, however,
does not prevent them from responding rapidly to potent
stimuli. These data therefore suggest that one of the crucial
functions of IL-21 is its implication in the survival and homeo-
static proliferation of human naive CD4+ T lymphocytes.
Methods
Reagents and cytokines
RPMI 1640 medium, FCS and b-mercaptoethanol (b-ME) were
purchased from Sigma Chemicals (St Louis, MO, USA). PBS,
penicillin–streptomycin, L-glutamine, MEM non-essential
amino acids and sodium pyruvate were obtained from Gibco
and Invitrogen (San Diego, CA, USA). Human AB serum was
provided by the Blood Bank of the University Hospital of
Geneva (Geneva, Switzerland). Ficoll-PaqueTM Plus was from
Amersham Biosciences (Uppsala, Sweden). Recombinant hu-
man IL-2 (rhIL-2) was obtained from Biogen, Inc. (Cambridge,
MA, USA) and recombinant human IL-21 (rhIL-21) was a gift
from D. C. Foster, Zymogenetics (Seattle, WA, USA).
Isolation of human CD4+ T lymphocytes and cultures
PBMCs were isolated from normal young donors by density-
gradient centrifugation. T cells were separated from PBMC
by negative selection with Dynabeads PanMouse IgG (Dynal
Biotech, Oslo, Norway) and a cocktail of antibodies to CD16,
CD19, CD14 and CD8 for selection of CD4+ T cells (Dako,
Copenhagen, Denmark). After negative selection, cells were
washed with PBS and T cells stained with PE-conjugated
mAb to CD45RO and FITC-conjugated mAb to CD4 (Dako).
CD45RO (naive) and CD45RO+ (memory) CD4+ T cells
were subsequently separated on a FACSvantage sorter
(BD PharMingenTM, San Diego, CA, USA). The selected
CD4+ cells were cultured for up to 3 weeks in RPMI 1640
medium supplemented with 10% heat-inactivated (HI) FCS,
5% HI AB serum, 100 U ml1 penicillin, 100 lg ml1 strepto-
mycin, 2 mM L-glutamine, 1% MEM non-essential amino
acids and 0.1 mM sodium pyruvate, 5 mM b-ME (at 5 3
105 M) (referred to as medium), autologous feeder cells ir-
radiated at 3500 rad and rIL-2 (25 ng ml1) or rIL-21 (25 ng
ml1) in 5% CO2 air humidified atmosphere at 37C.
Cytokine determination
Samples of conditioned media were subjected to ELISA for
the determination of IFN-c, IL-4 and IL-10 as described
previously (19). The sensitivity of all protein assays was
10–30 pg ml1.
T-cell proliferation assay in vitro
CD4+ T lymphocytes were isolated as above and cultured
for 7 days with rIL-2 (25 ng ml1) or rIL-21 (25 ng ml1).
Cells were plated at 25 3 105 cells per well in U-bottom 96-
well plates in enriched RPMI 1640 medium (as above) with
medium alone, coated a-CD3 (1 lg ml1) or anti-human
CD3 plus anti-human CD28-coated beads (Dynabeads
CD3/CD28 T cell expander kit, Dynal). Cells were incu-
bated in plates at 37C for 72 h, followed by the addition of
1 lCi of [3H]thymidine ([3H]TdR) (Perkin Elmer Life Scien-
ces, Inc.) for an additional 12 h. Cells were then harvested,
[
3
H]TdR incorporation per well was measured and the
means assessed for each triplicate.
Cell staining for flow cytometry
The following mouse anti-human mAbs and isotype-matched
control mAbs were purchased from BD PharMingenTM:
Cy-chrome-conjugated anti-CD4, PE-conjugated anti-CD45RO,
anti-CCR7, APC-conjugated anti-CD62L, FITC-conjugated
anti-annexin V, PE-conjugated propidium iodide (PI), FITC-
conjugated Bcl-2, PE-conjugated proliferating cell nuclear
antigen (PCNA), FITC-conjugated Ki-67 and isotype controls.
The following mouse anti-human mAbs and isotype-matched
control mAbs were obtained from Dako: FITC-conjugated
anti-CD4, PE-conjugated anti-CD4, Cy-chrome-conjugated
anti-CD45RA, FITC-conjugated goat anti-mouse IgG for anti-
human CCR7 and irrelevant, isotype-matched controls. Mu-
rine anti-human mAb—FITC-conjugated anti-CCR7—was
purchased from R&D Systems, Inc. (Minneapolis, MN, USA).
Three- to four-color immunofluorescence was performed to as-
sess surface marker expression on T cells activated by IL-2 or
IL-21. After 1–3 weeks of culture, CD4+ T lymphocytes were
washed twice with PBS (completed with 2% serum AB and
1& NaN3) and treated successively with FITC-, Cy-Chrome-
and/or PE-conjugated mAbs on ice for 30 min and washed
with PBS (completed with 2% serum AB and 1& NaN3).
For analysis of DNA incorporation, CD4+ T lymphocytes
were cultured with rIL-2 (25 ng ml1) and/or rIL-21 (25 ng
ml1) for 7 days. 10 lM of 5-bromo-2-deoxyuridine (BrdU)
solution was added to culture medium at designated time
points and cells were further processed for immunofluores-
cent staining as described in the instruction manual pro-
vided (BrdU flow kits, BD PharmingenTM).
For analysis of apoptotic cell death, CD4+ T lymphocytes
were cultured for 7 days in medium alone, with rIL-2 (25 ng
ml1) or rIL-21 (25 ng ml1). Cells were harvested and
stained with FITC-conjugated annexin V and PE-conjugated
PI in accordance with the supplier’s instructions (BD Phar-
MingenTM). For intracellular staining, CD4+ T cells were iso-
lated and washed once with PBS (completed with 2%
serum AB and 1% NaN3), and the intracellular proteins were
determined according to the supplier’s instructions using
the Cytofix/Cytoperm Kit from BD PharMingenTM. Cell stain-
ing was analyzed using FACSCalibur and CellQuest
Software (BD PharMingenTM).
Migration assay
Cell migration was evaluated using a chemotaxis micro-
chamber technique as described previously (20). The che-
moattractant recombinant human CCL21, anti-human
CCL21 (both obtained from R&D Systems) or control me-
dium was added at indicated concentrations to the 24-well
tissue culture plates. A polyvinylpyrrolidone-free polycarbon-
ate membrane with 8-lm pores for T lymphocytes (Nunc A/S)
was layered onto the wells. Five hundred microliter of cell
suspension (1 3 106 ml1 of T cells) was seeded into the
upper chamber. The chamber was incubated in 5% CO2 air
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humidified atmosphere at 37C for 60 min. At the end of the
incubation, filters were removed, and the cells that had
transmigrated into the lower chamber were counted.
Fluorochrome 5-carboxyfluorescein diacetate succinimidyl
ester labeling and analysis of T-cell proliferation in vitro
Human CD45RA+ (naive) CD4+ T cells were separated on
a FACSvantage sorter (BD Biosciences PharMingen, San
Diego, CA, USA). The selected CD4+ cells were labeled with
fluorochrome 5-carboxyfluorescein diacetate succinimidyl
ester (CFSE, Molecular Probe, Inc., Portland, OR, USA), as
described previously (21). CFSE was dissolved in dimethyl
sulfoxide and added for 15 min to the cell suspension at a
final concentration of 0.5 lM at 37C. The reaction was stop-
ped by the addition of PBS/10% FCS. The cells were
washed in PBS/10% FCS, re-suspended into RPMI 1640 me-
dium and cultured with IL-2 (25 ng ml1), IL-15 (25 ng ml1),
IL-21 (25 ng ml1) or a combination of cytokines for 7 days.
On day 7, cells were stained with Cy-chrome-conjugated
anti-CD45RA and PE-conjugated anti-CD45RO (BD PharMin-
genTM) for 30 min at 4C. After staining, cells were washed
once and re-suspended in 0.5 ml of PBS for analysis by flow
cytometry on a Becton-Dickinson FACS Sort equipped with
CellQuest Software. Live events were collected and ana-
lyzed by gating on to CD45RA+ or CD45RO+ CFSE+ cells.
Calculation of the frequency of proliferating T cell
Proliferation of CD45RA+ and CD45RO+ T cells in response
to cytokine stimulation was analyzed as described previ-
ously (22). With each round of cell division, the CFSE dye
spread equally between the daughter cells. By means of the
FACS acquisition software (CellQuestTM), the total number of
cells in each generation of proliferation was calculated and
the number of precursors generating the daughter cells was
determined by the following formula: y/2n (y = number of
cells in each peak, n = number of cell divisions). The fre-
quency of T-cell proliferation was then calculated by dividing
the total number of precursors by the total number of CFSE-
labeled cells.
Western blot analysis
CD45RA+ T lymphocytes were purified as described above
and cultured for 7 days with IL-2 (25 ng ml1). CD45RA+
T lymphocytes were isolated and the cells were then starved
overnight at 37C in RPMI 1640 medium supplemented with
1% HI FCS. Cells were harvested and re-suspended at 4 3
106 cells ml1 in RPMI medium supplemented with 1% HI
FCS, and 500 ll was placed in 2-ml polypropylene tubes
(Eppendorf) at 37C. After 1 h, cells were stimulated with IL-2
(25 ng ml1) or IL-21 (25 ng ml1). After the indicated time
of incubation, the reaction was stopped by the addition of
800 ll of ice-cold PBS and by centrifugation. Total cell
lysate was prepared and analyzed by western blot (23). The
blots were probed with anti-phospho Tyr701 STAT1, anti-
STAT3, anti-phospho Tyr703 STAT3 and anti-phospho Ser473
Akt (Upstate Biotechnology). Secondary HRP-conjugated
goat anti-rabbit antibodies were from Dako. Antibody-bound
proteins were detected by the Uptilight hrp Blot Chemilumi-
nescence substrate (Uptima).
Statistical analysis
Data were analyzed using the analysis of variance test, *P <
0.05 and **P < 0.001 being considered significant (Statview
5.1, SAS Institute Inc., Cary, NC, USA and GraphPad Prism
3.02).
Results
IL-21 preserves the naive phenotype of human T cells
(CD45RA+)
To determine if IL-21 would induce proliferation and activa-
tion of human naive T lymphocytes, naive CD4+ CD45RA+
human T cells were purified, sorted and exposed to IL-21
and/or IL-2. Since IL-21 acts in synergy with IL-15 in en-
hancing CD8+ proliferation and, in association with IL-2,
modifies NK cell surface markers (24), we determined the
role of IL-21 in naive CD4+ CD45RA+ human T cells alone or
in the presence of IL-2. CD4+ CD45RA+ T lymphocytes incu-
bated with IL-2 proliferated exponentially with time, as do
T cells cultured with IL-2 plus IL-21, but to a lesser extent
(Fig. 1A). As expected, IL-21 had little proliferative effect on
CD4+ CD45RA+ T lymphocytes (7), and between days 14
and 21 of culture, the number of T cells decreased and they
eventually died unless another TCGF was added. Cell sort-
ing (day 0) revealed a typical CD45RA rather than CD45RO
phenotype (Fig. 1B). Under all conditions, CD4+ T cells pre-
sented a similar phenotype after 7 days of culture (Fig. 1B).
However, when cells were cultured for as long as 14 and
21 days in the presence of rhIL-2, rhIL-21 or both simulta-
neously, their surface expression of CD45RA and CD45RO
varied as shown in Fig. 1(B). In the presence of IL-2, human
T lymphocytes tended to adopt a memory phenotype, with
the CD45RO+ marker replacing the CD45RA+ surface
marker (70% at day 7, 4% at day 14 and 3% at day 21 of
CD45RA+ CD45RO). With IL-21, 41% of T lymphocytes pre-
sented a naive phenotype at day 14, and a high percentage
of CD45RA+ cells was maintained until day 21 (70% of
CD45RA+ CD45RO) (Fig. 1B, Supplementary Table 1, avail-
able at International Immunology Online). T cells cultured in
the presence of both IL-2 and IL-21 cytokines continued to
present a naive phenotype at day 21 (27% of CD45RA+
CD45RO), suggesting that IL-21 may modify the potent dif-
ferentiating effect of IL-2.
If we consider the activated memory T-cell population to
be the sum of the percentage in CD4+ CD45RO+ T lympho-
cytes and the percentage in double-positive cells in terms
of activated CD4+ CD45RA+ T cells, as suggested by Arlettaz
et al. (25), the percentage of T lymphocytes with a memory
phenotype is even higher in cells treated with IL-2 than those
treated with IL-2 + IL-21. Consequently, the T-cell population
remaining at day 21 is enriched with CD4+ CD45RA+
T lymphocytes.
IL-21 maintains the co-expression of CCR7, CD45RA, and
CD62L on CD4+ T lymphocytes
To further characterize the naive phenotype of CD4+ T lym-
phocytes cultured with IL-21, several markers present on
the cell surface of naive T cells were analyzed. IL-21 main-
tained a marked co-expression of CD45RA and CCR7 at
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their cell surface, i.e. 89% in IL-21-cultured T cells compared
with 20% in IL-2-cultured T cells at day 14 (Fig. 2A), and
despite the presence of IL-2, IL-21 maintained a higher
expression of CCR7 on T cells (51% of CD45RA–CCR7
co-expression at day 14) (Fig. 2A, Supplementary Table 2,
available at International Immunology Online). At the same
time, we analyzed the co-expression of CD62L and CCR7
on CD45RA+ CD4+ T cells. As illustrated in Fig. 2(B), CD4+
T cells in the presence of IL-21 expressed simultaneously
high levels of both CCR7 and CD62L, whereas in the pres-
ence of IL-2, co-expression of these markers on the cell sur-
face of CD45RA+ CD4+ T cells decreased with time.
Co-culture of CD4+ T cells with both IL-2 and IL-21 resulted
in the expression of high levels of CCR7 and CD62L. Conse-
quently, IL-21 is able to maintain CD4+ T lymphocytes in
a naive phenotype as demonstrated by the persistence of
specific markers on their cell surface, such as CD45RA,
CCR7 and CD62L. Not only did IL-21 have a marked direct
effect on CD4+ T cells but also diminished the differentiation
and maturation of T cells induced by IL-2.
Fig. 1. IL-21 preserves the naive phenotype of T cells (CD45RA+
T cells). Naive CD4+ CD45RA+ T cells were obtained from
microbead-purified T cells by cell sorting. Purified naive T cells
(96% of CD45RA+ T cells as presented on the plot = day 0) were
cultured for 7, 14 and 21 days with IL-2 (25 ng ml1), IL-21 (25 ng ml1)
or both at the concentrations described in Methods. (A) Proliferation of
CD4+ CD45RA+ T cells over time. The number of cells recovered at
day 21 was as follows: IL-2 = 3.8 3 106 cells ml1, IL-21 = 0.81 3 106
cells ml1, IL-2 + IL-21 = 2 3 106 cells ml1. (B) The cells were
analyzed for expression of CD45RA+ versus CD45RO+ on their cell
surface. Cells were stained first with a Cy-chrome-labeled mAb to
CD45RA+ and then with PE-conjugated mAb to CD45RO+. This
experiment is representative of six individual experiments performed
and data were analyzed using the analysis of variance test. Statistical
analyses were performed to determine the differences between cells
treated by IL-2 or IL-21 versus those treated by IL-2 + IL-21 (*P < 0.05
and **P < 0.001) and differences between cells treated by IL-21
versus IL-2 (§P < 0.05 and §§P < 0.001) (Statview 5.1). The number
of cells recovered at day 21 was as follows: IL-2 = 2 3 106 cells ml1
(0.6 3 105 CD4+ CD45RA+ T cells ml1), IL-21 = 0.42 3 106 cells ml1
(3 3 105 CD4+ CD45RA+ T cells ml1), IL-2 + IL-21 = 1.2 3 106 cells
ml1 (3.2 3 105 CD4+ CD45RA+ T cells ml1). Quadrants were
generated based on staining profiles with control antibodies and
counted events were gated on remaining living cells.
Fig. 2. Co-expression of CCR7, CD45RA and CD62L by CD4+
T lymphocytes. Naive CD4+ CD45RA+ T cells were obtained by cell
sorting from microbead-purified T cells. Purified naive T cells were
cultured for 7 and 14 days with IL-2 (25 ng ml1), IL-21 (25 ng ml1) or
both, and their cell surface was analyzed for the expression of CCR7,
CD45RA and CD62L. The cells were stained with FITC-conjugated
mAb to CCR7, Cy-chrome-conjugated mAb to CD45RA and APC-
conjugated mAb to CD62L. (A) The cells were stained first with mAb
to CCR7 and then with FITC-conjugated goat mAb to IgG and IgM
and Cy-chrome-conjugated mAb to CD45RA. At day 14, the
comparison of CD45RA+/CCR7+ T cells treated with IL-2 versus
IL-21 yielded the following results: with IL-2 = 16 6 2 versus IL-21 =
59 6 15; P < 0.05. Quadrants were generated based on staining
profiles with control antibodies. (B) The cells were stained first with
FITC-conjugated mAb to CCR7, then incubated with APC-conjugated
mAb to CD62L and finally stained with Cy-chrome-conjugated mAb to
CD45RA. At day 14, the comparison of CD45RA+/CCR7+/CD62L+
T cells treated with IL-2 versus IL-2 + IL-21 yielded the following
results: with IL-2 = 25 6 5 versus IL-2 + IL-21 = 47 6 1.4: P < 0.05.
Quadrants were generated based on staining profiles with control
antibodies. Analysis was based on the expression of CD45RA/CCR7
or CD45RA/CCR7/CD62L at days 7 and 14. Data were analyzed using
the analysis of variance test. Statistical analyses were performed to
determine the differences between cells treated by IL-2 or IL-21
versus those treated by IL-2 + IL-21 (*P < 0.05 and **P < 0.001) and
differences between IL-21 versus IL-2-treated cells (§P < 0.05 and
§§P < 0.001). Data were analyzed using the analysis of variance test,
P < 0.05 and P < 0.0001 being considered significant (Statview 5.1).
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Chemotactic response of CD4+ T cells to recombinant human
CCL21
CCR7 controls homing to secondary lymphoid organs, that
in turn is crucial to homeostatic functions within the immune
system. The interaction of CCR7 and its ligand SLC facili-
tates the entry of T cells into lymph nodes and Peyer’s
patches (26). In view of these reports and in order to further
characterize the functional properties of the strongly en-
hanced expression of CCR7, we assessed the effect of
IL-21 on chemotaxis. Human CD4+ T lymphocytes express-
ing a high percentage of CCR7 on their cell surface, i.e.
cells cultured in the presence of IL-21, displayed a strong
chemotactic response to recombinant human CCL21, but
did not transmigrate in response to IL-8 (Fig. 3). The re-
sponse to CCL21 was inhibited by a specific mAb to
CCL21. These results confirm that naive CD4+ T cells
expressing CCR7 on their cell surface respond to their ligand
CCL21, which enables them to transmigrate in a double-
chamber system assay.
Differentiation and activation of CD4+ T cells by IL-21
The naive phenotype of T lymphocytes cultured with IL-21
did not indicate clearly if these cells survived, proliferated or
underwent apoptosis. To determine the likelihood of CD4+
T lymphocytes differentiating in the presence of IL-21, cells
(0.45 3 106 cells per ml) were cultured with IL-2 or IL-21.
After 7 days of culture, the concentration of T cells treated
with IL-2 amounted to 1.49 3 106 cells ml1 and that of cells
treated with IL-21 amounted to 0.83 3 106 cells ml1. All
cells were stained with mAbs to CD45RA and CD45RO and
sorted for a second time, gating on the CD45RA+ CD45RO
cell population (Fig. 4A and B). The sorted cells were cul-
tured once more at 0.2 3 106 cells per well with IL-2 or
IL-21 for an additional 7 days at the same concentrations.
As expected, the naive CD4+ T cells previously cultured with
IL-2 presented an activated/memory phenotype when cul-
tured once more with IL-2, 77% of cells expressing the
CD45RO+ marker (6.8 3 105 CD4+ CD45RO+ T cells ml1),
but only 18% of the T cells expressing CD45RA+ (1.6 3 105
CD4+ CD45RA+ T cells ml1) (Fig. 4B). In contrast, T lympho-
cytes pre-treated with IL-2 and then cultured with IL-21
maintained a naive phenotype, 66% of T cells expressing
CD45RA+ (2.4 3 105 CD4+ CD45RA+ T cells ml1) versus
28% of T cells expressing the CD45RO+ marker (1 3 105
CD4+ CD45RO+ T cells ml1) (Fig. 4B). Simultaneously, naive
CD4+ T cells previously cultured with IL-21 shifted into
activated/memory phenotype when cultured afterward with
IL-2, 35% of T cells expressing the CD45RO+ marker
(1 3 105 CD4+ CD45RO+ T cells ml1) but only 16% of
T lymphocytes expressing the CD45RO+ marker when cul-
tured with IL-21 (0.3 3 105 CD4+ CD45RO+ T cells ml1)
Fig. 3. Chemotactic response of CD4+ T cells to recombinant human
CCL21. Naive T cells were cultured for 10 days with IL-2 (25 ng ml1)
or IL-21 (25 ng ml1). Migration was assessed as described in
Methods. Spontaneous migration was subtracted. Chemotaxis of
human CD4+ T lymphocytes to recombinant human CCL21 was
inhibited by a specific mAb to CCL21. Data represent the percentage
of cells migrating to the lower chamber. Values are mean 6 SEM of
three separate experiments.
Fig. 4. CD4+ T cells cultured with IL-21 acquire an activated memory phenotype under stimulation. (A) Purified naive T cells were cultured for
7 days with IL-2 (25 ng ml1) or IL-21 (25 ng ml1). At day 7, the cells were stained first with Cy-chrome-labeled mAb to CD45RA+ and then with
PE-conjugated mAb to CD45RO+. Cells were sorted a second time, gating on CD45RA+-CD45RO T lymphocytes (quadrant). (B) The sorted
CD45RA+ T lymphocytes were cultured for an additional 7 days with IL-2 (25 ng ml1) or IL-21 (25 ng ml1), and their cell surface was analyzed
for expression of CD45RA+ versus CD45RO+ as described above. After these 7 days of culture, cell concentrations under each condition were as
follows: IL-2/IL-2 = 0.883 106 cells ml1, IL-2/IL-21 = 0.373 106 cells ml1, IL-21/IL-2 = 0.283 106 cells ml1, IL-21/IL-21 = 0.213 106 cells ml1.
The FACS results are based on an analysis of all the cells, with equal events gated on living cells; hence, the variation in cell recovery does not
skew the results or the percentage of CD45RA/CD45RO-positive cells. Values are mean6 SEM of three separate experiments and histograms are
representative of three individual experiments performed.
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(Fig. 4B, Supplementary Table 3, available at International
Immunology Online). The latter observation confirms that
T cells treated with IL-21 may be quiescent cells that main-
tain the ability to differentiate and proliferate in the presence
of more potent TCGFs like IL-2.
To confirm that naive IL-21-treated CD4+ T lymphocytes
can be reactivated, we assessed their proliferation and cyto-
kine production. CD4+ T lymphocytes cultured for 7 days
with IL-2 or IL-21 were placed in 96-well plates containing
coated a-CD3 or anti-human CD3 together with anti-human
CD28-coated beads and cultured for 72 h. The proliferation
of the cells was determined by [3H]TdR incorporation. Under
control conditions, the T cells pre-treated with IL-21 did not
proliferate further, contrary to IL-2-pre-treated T cells which
showed a slight persistent proliferation. IL-2-pre-treated
T cells proliferated to a similar extent whether stimulated with
a-CD3 or both anti-human CD3 and anti-human CD28-
coated beads (Fig. 5A). In contrast, stimulation of IL-21-
pre-treated T cells with a-CD3 induced very little proliferation
contrasting with the massive proliferation observed with anti-
human CD3 plus anti-human CD28-coated beads (Fig. 5A).
Analysis of cytokine production in these culture conditions
revealed that after stimulation with a-CD3 or anti-human
CD3 plus anti-human CD28-coated beads, IL-2 and IL-21
up-regulated the production of IFN-c, a Th1-type cytokine
(Fig. 5B). Of note, IL-21-treated T cells produced IFN-c to
a lesser extent when stimulated with a-CD3, whereas stimu-
lation with both anti-human CD3 and anti-human CD28-
coated beads prompted the marked production of IFN-c;
this effect was less pronounced on IL-2-treated T cells
(Fig. 5B). These data indicate that although IL-21 plays
a dual and dichotomous part on T cells by preserving a naive
phenotype, it also permits their proliferative response to vari-
ous stimuli (i.e. IL-2, a-CD3, co-stimulatory molecules) and
induces the secretion of lymphokines.
IL-21 maintains cell division in naive CD4+ T cells
The above experiments suggest that CD4+ T cells exposed
to IL-21 maintain their capacity to proliferate when exposed
to potent stimuli. To further assess the influence of IL-21 on
T-cell proliferation and viability, we labeled primary human
CD4+ CD45RA+ and CD45RO+ T cells with CFSE or BrdU. In
order to understand the mechanisms underlying the higher
proliferation observed with IL-2 as compared with IL-21,
CFSE-labeled CD4+ CD45RA+ T lymphocytes were cultured
as described in the legend for 7 days (Fig. 6). On day 7,
CFSE-stained cells were recovered and stained with Cy-
chrome-conjugated anti-CD45RA (Fig. 6A) and PE-
conjugated anti-CD45RO (Fig. 6B). Since CFSE spread
equally between daughter cells after cell division, both pat-
tern and frequency of proliferation of CD4+ T cells were ana-
lyzed by means of the CFSE-staining pattern, as described
in Methods. In the presence of IL-2, 17% of CFSE-labeled
CD4+ CD45RA+-gated T cells proliferated, contrasting with
the massive proliferation of 88% in the CD4+ CD45RO+-
gated T-cell population (Fig. 6A and B). With IL-21, only
12% of CD4+ CD45RA+-gated T cells divided, and CD4+
CD45RO+-gated T cells proliferated by ;4% (Fig. 6A and B).
When cultured with IL-2 and IL-21, the frequency of prolif-
erating CD4+ CD45RA+ and CD4+ CD45RO+ T cells was
not increased compared with IL-2 treatment alone (Fig. 6A
and B). To substantiate the above results, the proliferation of
CD4+ T cells was also tested in the presence of IL-15, a po-
tent inducer of T-cell proliferation, as well as IL-15 + IL-21.
IL-15 induced the proliferation of both CD4+ CD45RA+ and
CD4+ CD45RO+-gated T cells by 21 and 68%, respectively
(Fig. 6A and B). We observed that both CD4+ CD45RA+ and
CD4+ CD45RO+-gated T cells divided for multiple genera-
tions in the presence of both IL-15 and IL-21, with 29 and
91%, respectively, of CFSE-labeled T cells undergoing prolif-
eration (Fig. 6A and B). This confirms that IL-21 significantly
enhances the IL-15-driven proliferation of both naive and
memory CD4+ T cells (11). To analyze cell cycle entry and
progression of CD4+ T cells, sorted CD4+ CD45RA+ T cells
were cultured for 7 days with IL-2, IL-21 or IL-2 plus IL-21
and labeled with BrdU at different time points. The incorpo-
ration of BrdU in newly synthesized DNA was analyzed by
flow cytometry and by its staining associated with 7-AAD—a
dye binding to total DNA—cells that had actively synthe-
sized DNA were identified. As illustrated in Fig. 7, BrdU
pulsing of actively proliferating CD4+ T cells was performed
3 h and 45 min before harvesting. CD4+ T cells cultured with
Fig. 5. Stimulation of CD4+ T cells cultured with IL-21. (A) Purified naive CD4+ T cells were cultured for 7 days with IL-2 (25 ng ml1) (open bars)
or IL-21 (25 ng ml1) (closed bars). At day 7, the cells were washed once with PBS and cultured in plates coated with anti-human CD3 (1 lg ml1)
or anti-human CD3 plus anti-human CD28-coated beads for 72 h and pulsed with [3H]TdR for the final 12 h. Radioactivity incorporated into
proliferating cells was measured on a BetaplateTM, Wallac, Perkin Elmer Life Sciences, Inc. (Boston, MA, USA). Values are means 6 SEM from
three separate experiments involving three different blood samples. (B) Purified naive CD4+ Tcells were cultured for 7 days with IL-2 (25 ng ml1)
(open bars) or IL-21 (25 ng ml1) (closed bars). At day 7, the cells were washed once with PBS and cultured in plates coated with anti-human
CD3 (1 lg ml1) or anti-human CD3 plus anti-human CD28-coated beads for 48 h. Cultured supernatants were collected after 48 h and stored at
20C until use. Cultured supernatants were tested by ELISA for content in secreted IFN-c. Values are means 6 SEMs from three separate
experiments performed involving three different blood samples.
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IL-2, IL-21 or IL-2 plus IL-21 did not present major differen-
ces in their cell cycling subsets after 3 h of BrdU labeling
(Fig. 7). However, after 45 min of BrdU labeling, we ob-
served that in the presence of IL-21, CD4+ T cells mainly
resided in G0/G1 (R4), but few cells in phases S (R2) and
G2 + M (R3) of the cell cycle. In the case of CD4+ T cells
cultured with IL-2, a higher number of cells were in the
S (R2) and the G2 + M (R3) phases of the cell cycle, with
a decreased number of cells in the G0/G1 (R4) phase, com-
pared with cells exposed to IL-21. Similarly to IL-2 alone,
the combination of IL-2 and IL-21 resulted in 69% of CD4+
T cells in the G0/G1 (R4) phase, and a high number of cells
in the S (R2) and G2 + M (R3) phases of the cell cycle. Con-
sequently, the frequency of actively cycling cells is lower in
CD4+ T cells cultured with IL-21 than in those cultured with
IL-2.
IL-21 regulates the growth and cell cycle progression of naive
CD4+ T lymphocytes
Although IL-2 has the advantage of a stronger effect on pro-
liferation than IL-21, it is also conducive to cell death via
apoptosis. To compare the effects of both cytokines on apo-
ptosis and cell cycle progression, we determined the ex-
pression of survival proteins and proliferating nuclear
antigens. After 7 days of culture in control medium, >80% of
CD4+ T cells died according to double annexin V and PI
staining, the signature of cell death (Fig. 8A). In contrast, in
the presence of IL-2, cell viability was >80% (Fig. 8A), as
confirmed by the absence of annexin V or PI staining. With
the addition of IL-21, viability dropped to 44% but remained
substantial in comparison with control medium. The moder-
ate induction of apoptosis by IL-21 may correlate with the
Fig. 6. IL-21 and IL-15 jointly increase the proliferation of CD45RA+ T lymphocytes in vitro. Naive CD4+ CD45RA+ T cells were obtained from
microbead-purified Tcells by cell sorting. CFSE-labeled naive CD4+ CD45RA+ Tcells were cultured for 7 days with IL-2 (25 ng ml1), IL-21 (25 ng
ml1), IL-2 plus IL-21, IL-15 (25 ng ml1) or IL-15 plus IL-21. CFSE-stained cells were collected and stained with Cy-chrome-conjugated anti-
CD45RA (A) and PE-conjugated anti-CD45RO (B). Data are represented as percent of proliferation of CFSE-labeled CD4+ CD45RA+ Tcells (A) or
CD4+ CD45RO+ T cells (B). The frequency of T-cell proliferation was determined as follows: the total number of cells in each generation of
proliferation was calculated and the number of precursors that generated the daughter cells was determined by using the following formula: y/2n
(y = number of cells in each peak, n = number of cell divisions) (23,24). The frequency of T-cell proliferation was then analyzed by dividing the
total number of precursors by the total number of CFSE-labeled cells. Values are mean6 SEM of three separate experiments and histograms are
representative of three individual experiments performed.
Fig. 7. IL-21 induces proliferation of CD4+ CD45RA+ T cells as assessed by active DNA synthesis. Purified naive CD4+ CD45RA+ T cells were
cultured for 7 days with IL-2 (25 ng ml1), IL-21 (25 ng ml1) or both. At day 7, cells in culture were labeled with BrdU for the indicated time.
Immunofluorescent staining of the cells was then performed as described in Methods with antibodies to CD45RA, BrdU and 7-AAD. Flow
cytometric analysis was first gated on CD45RA+ T cells and then region gates were applied to the 7-AAD versus BrdU dot plot as suggested in
the BrdU Flow kit instruction manual. These region gates represent distinct cell cycle phases: R2 = S; R3 = G2 + M; R4 = G0/G1; R5 = apoptotic
cells. For each marker, isotype controls were added. Data are representative of three similar and independent experiments.
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down-regulation of the expression of Bcl-2, an anti-apoptotic
member of the Bcl-2 family. After 7 days of culture in the
presence of medium alone, IL-2 or IL-21, the expression of
Bcl-2 protein in T cells was measured by flow cytometry. As
shown in Fig. 8(B), CD4+ T cells cultured in control medium
did not express the Bcl-2 protein, indicating that all cells
were apoptotic. In contrast, CD4+ T cells cultured with IL-2
or IL-21 expressed high levels of the anti-apoptotic Bcl-2. It
follows that even though markers of apoptosis may be
slightly increased in naive CD4+ T lymphocytes, IL-21 favor-
ably affects naive CD4+ T-cell viability. Finally, to confirm that
IL-21 prompted cell cycle progression of purified naive
CD4+ T cells, the expression of proliferating nuclear antigens
was determined. Markers of cellular DNA synthesis, PCNA
and Ki-67—nuclear cell proliferation antigens expressed in
all active stages of the cell cycle—were adopted. Progres-
sion of the cell cycle was monitored via the expression of
PCNA and Ki-67 determined by flow cytometry. CD4+ T cells
cultured without any cytokines for 7 days failed to express
any PCNA or Ki-67 whatsoever (Fig. 8C and D). IL-2, which
effectively induced T-cell proliferation, increased the expres-
sion of the two proliferating nuclear antigens PCNA and
Ki-67 by 88%. IL-21 also induced, although to a lesser ex-
tent, the up-regulation of both proliferating nuclear antigens
with 67% of CD4+ T cells expressing PCNA and 48%
expressing Ki-67. A good correlation was found between
the two markers PCNA and Ki-67. These findings provide ev-
idence that IL-21 may control DNA synthesis, DNA repair
and cell cycle. With regard to Figs 7 and 8, when similar
experiments were performed at day 14, results were not dif-
ferent from those obtained at day 7 (data not shown).
IL-21 fails to signal through Akt
The weak effect of IL-21 on the proliferation of naive T lym-
phocytes may be due to differences in cell signaling. IL-2
mediated the activation of Jak1 and Jak3, which in turn in-
duced the phosphorylation of STAT3, STAT5 and to some ex-
tent of STAT1. IL-2 also mediated T-cell proliferation through
activation of the PI3K/Akt signaling pathway (27, 28). We
therefore performed an experiment to compare signal trans-
duction in human CD4+ T lymphocytes activated by IL-2 or
IL-21. A time course was run to determine phosphorylation
of STAT1 and STAT3 under these stimuli (data not shown),
and according to our results, maximum phosphorylation of
STAT1 and STAT3 was reached after 7–15 min. As illustrated
by Fig. 9, both IL-2 and IL-21 induced the phosphorylation
of STAT1 and STAT3, but contrary to IL-2, IL-21 failed to in-
duce the phosphorylation of Akt in T lymphocytes. These
results may explain why IL-2 has a more potent effect on
proliferation than IL-21.
Discussion
The population of activated T cells is continuously fed by
a pool of naive CD4 and CD8 T cells, which process ensures
they remain in the vicinity (29). Factors that contribute to the
division of peripheral naive T cells are not all understood,
but it is known that cytokines such as IL-7 play an important
role in this process (30). It also has to be remembered that
the number of peripheral blood naive T cells decreases pro-
portionally with age. Our data demonstrate that in the human
system IL-21 plays a crucial part in the survival of CD4+
T lymphocytes with a naive phenotype. In mice, the effect of
Fig. 8. IL-21 maintains the expression of survival and cell cycle
proteins in naive CD4+ CD45RA+ T cells. Purified naive CD4+
CD45RA+ T cells were cultured for 7 days in medium alone, with
IL-2 (25 ng ml1) or IL-21 (25 ng ml1). (A) At day 7, the cells were first
stained with annexin V and PI. The percentages of double-negative
subpopulations corresponding to viable cells are indicated in the
quadrant. (B–D) The same cells were also tested for their intra-
cytoplasmic levels of Bcl-2 (Fig. 7B), PCNA (Fig. 7C) or Ki-67
(Fig. 7D) by flow cytometry, as described in Methods. For each
marker, isotype controls were added. Values are mean 6 SEM of
three separate experiments and dot blots or histograms are
representative of three individual experiments performed.
Fig. 9. IL-21 does not induce Akt phosphorylation in CD4+ T cells.
Isolated CD45RA+ T cells (4 3 106 cells per 500 ll) were stimulated
with IL-2 (25 ng ml1) or IL-21 (25 ng ml1) for the indicated time. Total
cell lysates were analyzed by western blot, as described in Methods,
with antibodies to Tyr701-phosphorylated STAT1 (PY-STAT1), Tyr703-
phosphorylated STAT3 (PY-STAT3) and Ser473-phosphorylated Akt
(PY-Akt). Equal loading was ascertained by anti-STAT3 mAb. Left and
right panels represent two independent experiments performed at
different time points, up to 60 min for the left panel. These results are
representative of three independent experiments.
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IL-21 on naive CD4+ T cells has not been extensively stud-
ied, but in IL-21r/ mice the number of CD4+ T cells proved
normal in both thymus and peripheral lymphoid organ (12).
King et al. (5) demonstrated that IL-21 may play a major part
in the development of diabetes in non-obese diabetic mice,
due to an increase in T-cell proliferation and turnover cou-
pled with the absence of survival signals. It thus appears
that in mice IL-21 may favor the development of unstable,
self-destructive T cells implicated in the pathogenesis of au-
toimmune disease (5). But clearly it needs to be emphasized
that interspecies differences exist with respect to the biologi-
cal effects of IL-21 (7).
We demonstrate that in the human system IL-21 promotes
the survival and persistence of naive CD4+ T lymphocytes
while maintaining the expression of CD45RA, CD62L and
CCR7, the latter being related to the increased capacity of
T cells to transmigrate in response to CCL21. IL-21 maintains
a fraction of CD4+ T cells with a naive phenotype despite the
addition of IL-2. Consequently, the effects of IL-21 do not
duplicate those of IL-2, and the two cytokines have different
but possibly complementary effects at various stages of
T lymphocyte development. With TCR engagement (CD3)
and co-stimulation (CD28), the activation and proliferation of
naive CD4+ T cells pre-treated with IL-21 were as efficient
as T cell priming by IL-2. The fact that in our experiments
IL-21 failed to inhibit the production of IFN-c conflicts with
reports of IL-21 being conducive to Th2-type T cells (10, 31),
but it corroborates the work of others (8). The singular effect
of IL-21 on human CD4+ T cells is corroborated by different
reports (7, 10, 11, 18), as are its unique effects on other cell
types, i.e. CD8+ T (32, 33), NK cells (7, 16, 31, 34) and
B cells (35, 36). Others also suggest that IL-21, in synergy
with other cytokines (IL-2, IL-15, IL-18), might fulfill specific
functions on naive CD8+ T cells after induction of homeo-
static proliferation (35), that it enhances CD8+ T-cell
responses (24, 32) or the production of IFN-c by human NK
and T cells (8).
Control over T-cell survival and apoptosis is one of the
keys to regulating peripheral immune homeostasis. Resort-
ing to CFSE labeling (Fig. 6), we observed that IL-21 alone
had no effect on CD4+ T-cell proliferation, but in association
with IL-15, it enhanced the proliferation of CD45RA+ CD4+
T cells, similar to the synergistic effect observed on memory
CD4+ T cells (11). By determining DNA synthesis by means
of incorporated BrdU levels, we also demonstrate that even
if the frequency is faintly decreased, CD45RA+ CD4+ T cells
treated with IL-21 were able to synthesize DNA and to main-
tain cells in an active cycle. While IL-21 is known for its pro-
apoptotic effect on B lymphocytes (37, 38), we demonstrate
here that in CD4+ T cells, it increased the expression of
Bcl-2, an anti-apoptotic molecule, similar to the effect of
IL-2. These results, which confirm that IL-21 maintains the
frequency of naive CD4+ T cells by inhibiting apoptosis, are
also in keeping with the effect of a murine IL-21/Fc on
growth and survival of murine T lymphocytes through the in-
duction of Bcl-2 expression (39). Moreover, start and pro-
gression of the cell cycle are tightly regulated by the
activation of cyclins and cyclin-dependent protein kinases,
such as PCNA and Ki-67. Quiescent cells lack both, but af-
ter activation by cytokines (IL-2) or mitogens their expres-
sion is induced. The expression of these cell cycle markers
in naive CD4+ T cells confirms that IL-21 helps to maintain
the survival of naive CD4+ T cells. Finally, we demonstrate
that the binding of IL-21 or IL-2 to their respective receptors
triggers different pathways of intracellular signaling. The ac-
tivation of Akt by IL-2 depends on PI3K-mediated signals
provided by tyrosine residues within the IL-2Rb chain (14),
but the cc chain also engages signaling pathways through
its tyrosine residues and may activate Akt, resulting in the
up-regulation of Bcl-2 (27, 28). As the IL-21R complex lacks
the IL-2Rb chain, signaling through the cc chain may not be
sufficient to induce full activation of the PI3K/Akt pathway in
human CD4+ T cells, whereas in murine T lymphocytes,
IL-21 induces survival through the activation of the PI3K sig-
naling pathway (39). This is a further proof of IL-21 exerting
differential effects on human and murine T lymphocytes.
In summary, IL-21 is able to maintain populations of naive
CD4+ T cells and, by preventing the switch of one of the
CD4+ T-cell fractions toward a memory phenotype, IL-21
emerges as a novel regulator of the immune response and
as an additional cytokine involved in the transition of the im-
mune response from innate to adaptive immunity. Our com-
parison of IL-21 and IL-2 has revealed some differences in
the mechanisms of action underlying their regulation of
T cells. These results may provide an additional step toward
the understanding of IL-21 biology and novel insights into
the potential implication of this cytokine in the pathogenesis
of chronic autoimmune and inflammatory diseases.
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